German Tech Holding GmbH & Co. KGaA: Determination of the subscription price of the ongoing public subscription offer on 22 October 2026

Frankfurt am Main (pta030/20.10.2026/18:40 UTC+2)

Frankfurt/Main, 20 October 2026 – German Tech Holding (GTH) expects an initial external assessment of Zirnostics GmbH, of its zirconium-89-labelled PSMA tracer technology and its clinical rationale on 21 October 2026. It will determine and publish the subscription price for the ongoing public subscription offer of GTH treasury shares on 22 October 2026. The subscription period runs until 27 October 2026. Details of the subscription offer are set out in the announcements of 9 and 13 October as well as in the subscription offer published on 12 October 2026 together with further documents (https://germantechholding.com/index.php/for-shareholders/the-share/).

In the course of the ongoing public offer for the subscription of treasury shares, the proceeds of which are to fund the intended seizing of its exclusive investment opportunity in Zirnostics GmbH published on 7 October 2026, GTH has received purchase applications from shareholders, including oversubscription requests. Christoph Gerlinger, CEO and founder of GTH, the members of his family and their vehicles have also submitted their purchase applications and have exercised their subscription rights in full therein. In the event that the final subscription price is set at the lower end of the subscription price range, GG Beteiligungen UG has furthermore undertaken to acquire all shares not subscribed for by shareholders of GTH. Christoph Gerlinger holds an indirect interest of just under 50 % in GG Beteiligungen UG. Christoph Gerlinger's family's stake in GTH could thus reach up to 77 %.

About German Tech Holding

German Tech Holding (GTH) is an investment company founded in 2012 and based in Frankfurt am Main.

During its active years as a leading German venture capital provider under the name German Startups Group, GTH held stakes with great success in, among others, Chrono24, Delivery Hero, Fiagon, Mister Spex, Remerge and Scalable Capital. To this day it holds investments including AuctionTech, SoundCloud and Thinksurance. Through its SaaS-based white-label solution PropNow for digital bidding and offer processes in the real estate market, AuctionTech is the European market leader.

GTH pursues opportunities in the fields of artificial intelligence and life sciences/biotech. Cognicare AI, a spin-off from GTH's investment in the company builder Softmax AI, addresses the structurally growing market for senior care facilities with highly sought-after AI applications. In the field of life science, GTH is examining an investment opportunity in Zirnostics GmbH that has presented itself and has signed a term sheet in this regard. Zirnostics is preparing a clinical trial for the approval of its disruptive tracer for PSMA-PET/CT imaging in prostate cancer, which is up to 100-fold superior to legacy tracers in terms of tumour-to-background contrast and has already been successfully clinically tested for years in several hundred patients.

Securities ID number A1MMEV

ISIN DE000A1MMEV4

Symbol GTH

Further information: germantechholding.com

Investor Relations Contact

Rosenberg Strategic Communications
Mario Groß
m.gross@rosenbergsc.com

Important notice

The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are exclusively authoritative for the currently ongoing public offer. This press release constitutes neither investment advice nor an investment recommendation.

This press release contains forward-looking statements based on current assessments of the management. Such statements are subject to risks and uncertainties, in particular with regard to the completion of the investment transaction, the course of clinical trials, the granting of FDA and EMA approvals under pharmaceutical law and market developments. Actual developments may therefore differ materially. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation.

Disclaimer

This publication is advertising. It constitutes neither an offer to sell nor a solicitation to purchase or subscribe for securities in any jurisdiction, in particular not in the United States of America. An investment decision may be made exclusively on the basis of the information document prepared by the issuer pursuant to Article 1 (4) subpara. 1 lit. db) of the Prospectus Regulation and in accordance with the requirements set out in Annex IX of the Prospectus Regulation, which is published at http://www.germantechholding.com under the heading "For Shareholders" (https://germantechholding.com/index.php/for-shareholders/the-share/) and has been filed with the Federal Financial Supervisory Authority ("BaFin"). BaFin, as the competent national authority, has neither reviewed nor approved this document. Potential investors should read the information document before making an investment decision in order to fully understand the potential risks and opportunities of the decision to invest in the securities.

This publication is not intended, either directly or indirectly, for distribution or dissemination into or within the United States of America (including its territories and possessions, any state of the United States or the District of Columbia) or to publications with a general circulation in the United States of America. The securities are not and will not be registered under the provisions of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may be sold or offered for purchase in the United States of America only with prior registration under the provisions of the Securities Act as currently in force or, without prior registration, only on the basis of an exemption. The issuer does not intend to register the offer of securities in whole or in part in the United States of America or to conduct a public offering in the United States of America.

Outside Germany, this publication is directed only at, and is intended exclusively for, those persons in member states of the EEA who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation ("qualified investors"). In addition, in the United Kingdom this publication is distributed only to, and is directed only at, those qualified investors (i) who have professional experience in matters relating to investments within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) who are high net worth companies within the meaning of Article 49(2)(a) to (d) of the Order, or (iii) who are other persons to whom this publication may lawfully be communicated.

This publication is not an offer to purchase securities in Canada, Japan or Australia.

Forward-looking statements

This announcement contains forward-looking statements based on current assessments of the management. Such statements are subject to risks and uncertainties, in particular with regard to the completion of the investment transaction, the course of clinical trials, the granting of FDA and EMA approvals under pharmaceutical law and market developments. Actual developments may therefore differ materially. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation. The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are solely authoritative for the public offer.

(end)

Emitter:	German Tech Holding GmbH & Co. KGaA Humboldtstraße 60B 60318 Frankfurt am Main Germany
Contact Person:	Investor Relations
Phone:	+49 69 348690520
E-Mail:	ir@germantechholding.com
Website:	germantechholding.com
ISIN(s):	DE000A1MMEV4 (Share)
Stock Exchange(s):	Free Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX